Amgen said its experimental weight loss injection helped patients lose up to 20% of their weight on average after a year, with no plateau, in a critical mid-stage trial.
But shares of Amgen fell on Tuesday, as the results appear to be at the lower end of Wall Street’s lofty expectations for the drug.
The data shed light on how MariTide may measure up to blockbuster weight loss injections from Novo Nordisk and Eli Lilly, and a crowded field of treatments being developed by other drugmakers.
